Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.55 CAD -0.86%
Market Cap: 133.9m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Biosyent Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biosyent Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Biosyent Inc
XTSX:RX
Net Change in Cash
CA$3.1m
CAGR 3-Years
70%
CAGR 5-Years
N/A
CAGR 10-Years
0%
Bausch Health Companies Inc
TSX:BHC
Net Change in Cash
-$30m
CAGR 3-Years
29%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Net Change in Cash
-CA$84.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Net Change in Cash
$290.4m
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Net Change in Cash
$177.6m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
166%
C
Curaleaf Holdings Inc
CNSX:CURA
Net Change in Cash
-$79.6m
CAGR 3-Years
-129%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biosyent Inc
Glance View

Market Cap
133.9m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
9.83 CAD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Biosyent Inc's Net Change in Cash?
Net Change in Cash
3.1m CAD

Based on the financial report for Sep 30, 2024, Biosyent Inc's Net Change in Cash amounts to 3.1m CAD.

What is Biosyent Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
0%

Over the last year, the Net Change in Cash growth was 113%. The average annual Net Change in Cash growth rates for Biosyent Inc have been 70% over the past three years .

Back to Top